<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article-commentary" dtd-version="1.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="issn">1043-3155</journal-id>
<journal-id journal-id-type="nlm-ta">Pediatr Neurol Briefs</journal-id>
<journal-id journal-id-type="pmc">pedneurbriefs</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatr Neurol Briefs</journal-id>
<journal-title-group>
<journal-title>Pediatric Neurology Briefs</journal-title>
<abbrev-journal-title>Pediatr Neurol Briefs</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2166-6482</issn>
<issn pub-type="ppub">1043-3155</issn>
<issn-l>2166-3155</issn-l>
<publisher>
<publisher-name>Pediatric Neurology Briefs Publishers</publisher-name>
<publisher-loc>Chicago, IL, USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PNB-8-89</article-id>
<article-id pub-id-type="doi">10.15844/pedneurbriefs-8-12-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Infectious Disorders</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v2">
<subject>Neurology</subject>
<subject>Pediatrics</subject>
<subject>Nervous System Diseases</subject>
<subject>Child Development</subject>
<subject>Brain Diseases</subject>
<subject>Neurosurgery</subject>
<subject>Child</subject>
<subject>Infant</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Perinatal HIV and Neurodevelopment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0173-7931</contrib-id>
<name>
<surname>Millichap</surname>
<given-names>J. Gordon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
</contrib-group>
<aff id="AF0001">
<label>1</label>Division of Neurology, Children&#x0027;s Memorial Hospital, Chicago, IL</aff>
<aff id="AF0002">
<label>2</label>Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
<author-notes>
<corresp id="cor1"><label>&#x002A;</label>Correspondence: Dr. J. Gordon Millichap, E-mail: <email xlink:href="jgmillichap@northwestern.edu">jgmillichap@northwestern.edu</email>
</corresp>
</author-notes>
<pub-date date-type="pub" publication-format="print">
<month>12</month>
<year>1994</year>
</pub-date>
<pub-date date-type="pub" publication-format="electronic">
<day>01</day>
<month>06</month>
<year>2016</year>
</pub-date>
<volume>8</volume>
<issue>12</issue>
<fpage>89</fpage>
<lpage>89</lpage>
<permissions>
<copyright-statement>Copyright: &#x00A9; 1994 The Author(s)</copyright-statement>
<copyright-year>1994</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This work is licensed under the <uri xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</uri>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<related-article id="R1" related-article-type="commentary-article" ext-link-type="pmid" xlink:href="7971006" vol="94" page="883">
<article-title>Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life</article-title>
</related-article>
<abstract abstract-type="web-summary" specific-use="electronic-only">
<p>The natural history of HIV disease and neurodevelopmental disorders in 21 perinatally infected children were examined in a collaborative prospective study sponsored by the National Institute of Child Health &#x0026; Human Development, Rockville, MD.</p>
</abstract>
<kwd-group>
<kwd>Neurodevelopmental Disorders</kwd>
<kwd>Motor Impairments</kwd>
<kwd>Zidovudine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The natural history of HIV disease and neurodevelopmental disorders in 21 perinatally infected children were examined in a collaborative prospective study sponsored by the National Institute of Child Health &#x0026; Human Development, Rockville, MD. Bayley Scales were compared during the first 24 months of life in the infected group, in 65 seroreverted children born to HIV-infected mothers, and 95 non-HIV-infected children of non-HIV-infected mothers. Mental and motor impairments (&#x003C;50) in all functional areas were present predominantly in HIV-infected children who developed AIDS in the first 2 years. These children also had small head circumferences and neurologic abnormalities. Children with AIDS manifesting only lymphoid interstitial pneumonitis showed inconsistent, mild, developmental impairments delayed in onset. HIV-infected children without AIDS and uninfected children were not developmentally impaired. [<xref ref-type="bibr" rid="CIT0001">1</xref>]</p>
<disp-quote>
<p>COMMENT. Children born to HIV-infected mothers who develop AIDS are at very high risk for serious neurodevelopmental disorders. Those without symptoms of AIDS may develop normally but require frequent monitoring to determine need for therapy. Uninfected children of HIV-infected mothers are not affected by the viral exposure.</p>
<p>Growth was a prognostic indicator in children with HIV-infection treated with zidovudine in the collaborative AIDS Clinical Trials Group. Survival rate after 4 years follow-up was 44%. Risk of death was greatest in children with CD4<sup>+</sup> lymphocyte percentages &#x003C;20%, if weight-for-age z score was &#x003C;2 at entry, and if weight gain was &#x003C;25th percentile rate in the first 6 months of therapy. [<xref ref-type="bibr" rid="CIT0002">2</xref>]</p>
</disp-quote>
</body>
<back>
<ref-list>
<ref id="CIT0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nozyce</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hittelman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Muenz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Durako</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Willoughby</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life</article-title>
<source>Pediatrics</source>
<year>1994</year>
<month>Dec</month>
<volume>94</volume>
<issue>6 Pt 1</issue>
<fpage>883</fpage>
<lpage>891</lpage>
<pub-id pub-id-type="pmid">7971006</pub-id>
</element-citation>
</ref>
<ref id="CIT0002">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKinney</surname>
<given-names>RE</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Wilfert</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group</article-title>
<source>J Pediatr</source>
<year>1994</year>
<month>Nov</month>
<volume>125</volume>
<issue>5 Pt 1</issue>
<fpage>728</fpage>
<lpage>733</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3476(06)80170-8</pub-id>
<pub-id pub-id-type="pmid">7965424</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>